Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo

Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo

The therapeutic options for patients with relapsed or metastatic myxoid liposarcoma (MLS) remain scarce and there is currently no targeted therapy available. Inhibition of the HSP90 family of chaperones has been suggested as a possible therapeutic option for patients with MLS. However, the clinical...

Full description

Bibliographic Details
Main Authors: Christoffer Vannas, Lisa Andersson, Soheila Dolatabadi, Parmida Ranji, Malin Lindén, Emma Jonasson, Anders Ståhlberg, Henrik Fagman, Pierre Åman
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biomedicines
Subjects:
myxoid liposarcoma
HSP90 inhibition
receptor tyrosine kinase signaling
drug treatment
combination therapy
Online Access:https://www.mdpi.com/2227-9059/10/3/624

Similar Items

Similar Items